Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Instituto Rosenbusch's Enterprise Value is ARS8,845 Mil.
Instituto Rosenbusch's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ARS-1,325 Mil. Therefore, Instituto Rosenbusch's EV-to-FCF for today is -6.68.
The historical rank and industry rank for Instituto Rosenbusch's EV-to-FCF or its related term are showing as below:
BUE:ROSE'
s EV-to-FCF Range Over the Past 10 Years
Min: -624.69 Med: 6.91 Max: 4193.46
Current: -6.77
During the past 13 years, the highest EV-to-FCF of Instituto Rosenbusch was 4193.46. The lowest was -624.69. And the median was 6.91.
BUE:ROSE's EV-to-FCF is ranked worse than 100% of 565
companies
in the Drug Manufacturers industry
Industry Median: 20.2
vs BUE:ROSE: -6.77
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Instituto Rosenbusch (BUE:ROSE) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Instituto Rosenbusch's PE Ratio (TTM) for today is calculated as:
Instituto Rosenbusch's share price for today is ARS157.50.
Instituto Rosenbusch's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ARS-100.149.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Instituto Rosenbusch EV-to-FCF Related Terms
Instituto Rosenbusch EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Instituto Rosenbusch's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Instituto Rosenbusch's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Instituto Rosenbusch EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Instituto Rosenbusch's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Instituto Rosenbusch's EV-to-FCF falls into.
Instituto Rosenbusch's current Enterprise Value is ARS8,845 Mil.
Instituto Rosenbusch's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ARS-1,325 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Instituto Rosenbusch (BUE:ROSE) has a EV-to-FCF of -6.68 as of Sep. 04, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Instituto Rosenbusch and its competitors. According to the industry distribution chart, Instituto Rosenbusch ranks #999999 out of 565 companies in the Drug Manufacturers industry.
Is Instituto Rosenbusch's EV-to-FCF too high?
Instituto Rosenbusch's current EV-to-FCF is -6.68. Based on the distribution chart, Instituto Rosenbusch ranks #999999 out of 565 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Instituto Rosenbusch has a GF Score™ of 22/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Instituto Rosenbusch's EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Instituto Rosenbusch ranks #999999 out of 565 companies for EV-to-FCF. This places Instituto Rosenbusch in the lower half of its industry. The industry median EV-to-FCF is 20.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.20, based on 565 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Instituto Rosenbusch and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Instituto Rosenbusch's current EV-to-FCF is -6.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Instituto Rosenbusch stock overvalued right now?
Based on GuruFocus' analysis, Instituto Rosenbusch (BUE:ROSE) is currently considered Significantly Overvalued. The stock's GF Value™ is ARS65.49, compared to a current price of ARS157.50 — trading 140.5% above its estimated fair value. The current EV-to-FCF is -6.68. Instituto Rosenbusch's overall GF Score™ is 22/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Instituto Rosenbusch (BUE:ROSE), the current EV-to-FCF is -6.68 as of Sep. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Instituto Rosenbusch (BUE:ROSE) Overvalued in 2026?
Based on GuruFocus' analysis, Instituto Rosenbusch stock appears to be overvalued.
The current stock price of ARS157.50 is trading 140.5% above its estimated GF Value™ of ARS65.49.
GuruFocus considers Instituto Rosenbusch to be Significantly Overvalued.
Key valuation signals for BUE:ROSE:
EV-to-FCF: -6.68
GF Value™: ARS65.49 vs. price of ARS157.50 (140.5% above fair value)
No single metric tells the full story. See the BUE:ROSE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Instituto Rosenbusch SA is a pharmaceutical company based in Argentina. The company is engaged in the processing and industrialization of biological, chemical, pharmaceutical products of any kind, nature or destination, preferably for veterinary use or intended to combat pests and diseases of the agricultural exploitation. The company has line of products such as Biologicals and pharmaceuticals. Biologicals offer Campy 3, Cultivac 6M and Bovine Antibrucelosis. Pharmaceuticals offer Diclosan A Intrammamary, Diclosan S Intrammamary and Mastilina V-S.
22GF Score
Get the complete analysis for BUE:ROSE
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BUE:ROSE has been successfully added to your 
